• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用表达HIV-1包膜蛋白的DNA和非感染性HIV-1颗粒在小鼠中引发抗体反应。

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

作者信息

Lu S, Santoro J C, Fuller D H, Haynes J R, Robinson H L

机构信息

Department of Pathology, University of Massachusetts Medical Center, Worcester 01655, USA.

出版信息

Virology. 1995 May 10;209(1):147-54. doi: 10.1006/viro.1995.1238.

DOI:10.1006/viro.1995.1238
PMID:7747464
Abstract

Two DNA constructs encoding portions of the human immunodeficiency virus type-1 (HIV-1) genome have been used to raise antibody responses in BABL/c mice. One DNA (pNL4-3.env) expresses the natural form of the envelope glycoprotein (Env) of HIV-1-NL4-3 (NL4-3). The second (pNL4-3.dpol) produces noninfectious NL4-3 particles. These two DNAs (alone or in combination) raised only transient titers of anti-Env IgG. In the same group in which pNL4-3.dpol DNA raised only transient antibody responses to Env, this DNA raised persistent antibody responses to the p24 virion capsid protein (CA). Antibody responses to Env and CA also showed different abilities to be boosted. The final boosts of pNL4-3.dpol DNA increased titers of anti-CA antibody, but failed to boost the falling titers of anti-Env antibody. At peak titers of anti-Env activity, sera with relatively low ELISA titers of anti-Env IgG (end points of 1:6250) had good titers of neutralizing antibody (approximately 1:3800 for 50 TCID50 of NL4-3). At the end of the experiment (a time when anti-Env antibodies had fallen to near background levels), in vitro-restimulated splenocytes from both pNL4-3.env and pNL4-3.dpol DNA vaccine groups exhibited similar cytotoxic activity.

摘要

两种编码人类免疫缺陷病毒1型(HIV-1)基因组部分片段的DNA构建体已被用于在BABL/c小鼠中引发抗体反应。一种DNA(pNL4-3.env)表达HIV-1-NL4-3(NL4-3)包膜糖蛋白(Env)的天然形式。第二种(pNL4-3.dpol)产生无感染性的NL4-3颗粒。这两种DNA(单独或联合使用)仅引发了短暂的抗Env IgG滴度。在pNL4-3.dpol DNA仅引发对Env的短暂抗体反应的同一组中,该DNA引发了对p24病毒体衣壳蛋白(CA)的持续抗体反应。对Env和CA的抗体反应在增强能力上也表现出差异。pNL4-3.dpol DNA的最终增强提高了抗CA抗体的滴度,但未能提高逐渐下降的抗Env抗体滴度。在抗Env活性的峰值滴度时,抗Env IgG ELISA滴度相对较低(终点为1:6250)的血清具有良好的中和抗体滴度(对于50个TCID50的NL4-3,约为1:3800)。在实验结束时(抗Env抗体已降至接近背景水平的时间),来自pNL4-3.env和pNL4-3.dpol DNA疫苗组的体外再刺激脾细胞表现出相似的细胞毒性活性。

相似文献

1
Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.使用表达HIV-1包膜蛋白的DNA和非感染性HIV-1颗粒在小鼠中引发抗体反应。
Virology. 1995 May 10;209(1):147-54. doi: 10.1006/viro.1995.1238.
2
Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.利用DNA免疫和重组痘苗病毒加强免疫筛选HIV-1 Env糖蛋白产生中和抗体的能力。
Virology. 1997 Apr 14;230(2):265-74. doi: 10.1006/viro.1997.8478.
3
Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.病毒样颗粒表面嵌入膜的HIV-1包膜引发的免疫反应比可溶性包膜更广泛。
Virology. 2007 Feb 20;358(2):334-46. doi: 10.1016/j.virol.2006.08.032. Epub 2006 Sep 28.
4
Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.构建一种HIV-1肽疫苗,该疫苗包含与V3环肽18相连的多决定簇辅助肽,经两次免疫后在多种MHC单倍型小鼠中诱导强烈的中和抗体反应。
J Immunol. 1993 Jun 15;150(12):5647-65.
5
Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.由异源弹状病毒初免-加强免疫方法诱导的强烈细胞和体液抗HIV Env免疫反应。
Virology. 2005 Jan 5;331(1):82-93. doi: 10.1016/j.virol.2004.10.018.
6
Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.呈现嵌合包膜糖蛋白的重组人免疫缺陷病毒Pr55gag病毒样颗粒可诱导细胞毒性T细胞和中和抗体。
Virology. 1997 Aug 18;235(1):26-39. doi: 10.1006/viro.1997.8668.
7
Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.利用嵌合gag-env病毒样颗粒开发艾滋病毒/艾滋病疫苗。
Biol Chem. 1999 Mar;380(3):353-64. doi: 10.1515/BC.1999.047.
8
HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.HIV-1包膜糖蛋白gp140三聚体可引发中和抗体,但无法有效诱导构象依赖性抗体。
Vaccine. 2006 Jun 29;24(26):5442-51. doi: 10.1016/j.vaccine.2006.03.063. Epub 2006 Apr 3.
9
Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.多基因DNA疫苗对小鼠体内的HIV-痘苗病毒攻击具有高水平的保护作用。
Vaccine. 2004 Sep 9;22(27-28):3676-90. doi: 10.1016/j.vaccine.2004.03.015.
10
Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.口服DNA疫苗可促进对HIV包膜糖蛋白的黏膜和全身免疫反应。
Virology. 2000 Feb 1;267(1):8-16. doi: 10.1006/viro.1999.0093.

引用本文的文献

1
A Novel Codon-optimized SIV Gag-pol Immunogen for Gene-based Vaccination.一种用于基因疫苗接种的新型密码子优化的猴免疫缺陷病毒Gag-pol免疫原。
Virol Rep. 2015 Dec 1;5:47-55. doi: 10.1016/j.virep.2015.03.002. Epub 2015 Mar 10.
2
DNA Immunization for HIV Vaccine Development.用于HIV疫苗开发的DNA免疫接种
Vaccines (Basel). 2014 Feb 25;2(1):138-59. doi: 10.3390/vaccines2010138.
3
DNA immunization.DNA免疫
Curr Protoc Microbiol. 2013 Nov 5;31:18.3.1-18.3.24. doi: 10.1002/9780471729259.mc1803s31.
4
Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.在非人灵长类动物中,HIV-1 JRFL 包膜糖蛋白三聚体引发的强效中和抗体。
J Virol. 2013 Dec;87(24):13239-51. doi: 10.1128/JVI.01247-13. Epub 2013 Sep 25.
5
Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1).翻译:翻译后细胞内运输决定了表达人类免疫缺陷病毒 1 型(HIV-1)Gag 抗原的 DNA 疫苗引发的免疫反应类型。
Hum Vaccin Immunother. 2013 Oct;9(10):2095-102. doi: 10.4161/hv.26009. Epub 2013 Aug 13.
6
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine.新型工程化 HIV-1 组 C 基于合成共识的包膜 DNA 疫苗的免疫原性。
Vaccine. 2011 Sep 22;29(41):7173-81. doi: 10.1016/j.vaccine.2011.05.076. Epub 2011 Jun 7.
7
Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines.肽和辅助依赖型腺病毒疫苗对黏膜SHIV攻击的保护作用。
Viruses. 2009 Dec 1;1(3):920. doi: 10.3390/v1030920.
8
Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes.免疫接种表达α-半乳糖表位的 gp120/p24 融合蛋白疫苗后 HIV-1 p24 和 gp120 的免疫原性增强。
Vaccine. 2010 Feb 17;28(7):1758-65. doi: 10.1016/j.vaccine.2009.12.015. Epub 2009 Dec 22.
9
Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).抗1型人类免疫缺陷病毒(HIV-1)中和抗体诱导方面的进展。
BioDrugs. 2009;23(3):137-53. doi: 10.2165/00063030-200923030-00001.
10
The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods.通过肌肉注射、电穿孔和基因枪方法递送的DNA疫苗的相对免疫原性。
Vaccine. 2008 Apr 16;26(17):2100-10. doi: 10.1016/j.vaccine.2008.02.033. Epub 2008 Mar 6.